Last updated: October 5, 2026
ARAKODA, the branded tafenoquine product from 60 Degrees Pharmaceuticals, is a niche malaria-prevention drug with FDA approval, limited direct competition, and a small commercial base. Its financial trajectory depends more on military procurement, government and institutional channels, travel-medicine adoption, and expansion into additional malaria markets than on conventional retail prescribing.
The product has several commercial advantages: a weekly maintenance schedule, a short pretravel dosing regimen, and a differentiated position against daily atovaquone/proguanil and doxycycline. Its constraints are equally significant: a restricted adult population, mandatory G6PD testing, low malaria-prophylaxis volumes in the United States, limited sales infrastructure, and competition from generic drugs.
What is ARAKODA and who markets it?
ARAKODA is the U.S. brand name for tafenoquine succinate, an 8-aminoquinoline antimalarial. 60 Degrees Pharmaceuticals markets the product in the United States. The company obtained U.S. approval through New Drug Application 210607 in July 2018.[1]
ARAKODA is approved for malaria prophylaxis in adults. The labeled regimen is:
| Product characteristic |
ARAKODA |
| Active ingredient |
Tafenoquine succinate |
| Strength |
100 mg tafenoquine base per tablet, equivalent to 125 mg tafenoquine succinate |
| Dosage form |
Oral tablet |
| U.S. indication |
Malaria prophylaxis in adults |
| Typical regimen |
Loading dose before travel followed by weekly maintenance dosing |
| Required screening |
Quantitative G6PD testing |
| Key contraindications |
G6PD deficiency, breastfeeding when the infant’s G6PD status is unknown or deficient, and certain hypersensitivity risks |
| U.S. sponsor |
60 Degrees Pharmaceuticals |
| FDA approval |
July 20, 2018 |
The weekly dosing schedule differentiates ARAKODA from daily doxycycline and daily atovaquone/proguanil. Tafenoquine cannot be used safely without G6PD screening because hemolytic anemia can occur in patients with deficient G6PD activity.[1]
How large is the ARAKODA market?
The addressable market is commercially narrow but strategically valuable. U.S. malaria prophylaxis demand is tied to international travel, military deployment, humanitarian operations, government personnel, and occupational travel. The number of U.S. travelers visiting malaria-endemic regions is large, but only a fraction receive prescription prophylaxis, and ARAKODA competes for a subset of that prescribing.
ARAKODA’s principal market segments are:
- Travelers seeking a weekly regimen.
- Military and government personnel.
- Travelers for whom adherence to daily prophylaxis is a concern.
- Institutional buyers seeking an alternative to daily drugs.
- International markets where tafenoquine is approved or can be supplied through local partners.
The product does not have the volume characteristics of a mass-market chronic therapy. Revenue depends on prescription capture, institutional contracts, and periodic travel recovery rather than a large recurring patient population.
How does ARAKODA compare with competing malaria drugs?
| Product |
Active ingredient |
Dosing pattern |
Key commercial advantage |
Main limitation |
| ARAKODA |
Tafenoquine |
Loading regimen plus weekly maintenance |
Weekly dosing and long half-life |
G6PD testing and narrow adult label |
| Malarone and generics |
Atovaquone/proguanil |
Daily |
Broad travel-medicine familiarity and generic availability |
Daily dosing and higher cost than some alternatives |
| Doxycycline and generics |
Doxycycline |
Daily |
Low cost and broad availability |
Photosensitivity, gastrointestinal effects, daily adherence |
| Primaquine |
Primaquine |
Daily |
Low-cost 8-aminoquinoline option |
G6PD testing and daily dosing |
| Lariam and generics |
Mefloquine |
Weekly |
Weekly dosing and established use |
Neuropsychiatric and cardiac safety concerns |
ARAKODA’s strongest commercial argument is adherence. Its weakest commercial argument is price relative to generic alternatives. In travel medicine, prescribers may also select a familiar generic drug unless the patient specifically values weekly dosing or has an adherence concern.
What is the financial trajectory of 60 Degrees Pharmaceuticals?
60 Degrees is a single-product or near-single-product commercial company whose financial performance is closely linked to ARAKODA. Public filings indicate a small revenue base, operating losses, and continuing dependence on external financing and commercial expansion.[2]
The company’s financial profile has four defining characteristics:
- Revenue is growing from a low base.
- Gross-margin potential is higher than the current scale of sales.
- Selling, general, administrative, regulatory, and development costs remain high relative to revenue.
- Cash requirements create dilution and financing risk.
What drives ARAKODA revenue?
ARAKODA revenue is influenced by:
| Driver |
Effect on revenue |
| International travel volume |
Increases prescriptions through travel clinics and retail channels |
| Government and military procurement |
Can create larger, less seasonal orders |
| Travel-clinic adoption |
Expands physician familiarity and patient access |
| Retail availability |
Reduces friction for prescriptions and refills |
| G6PD testing access |
Determines whether patients can complete the prescribing process |
| Generic pricing |
Limits price expansion |
| Seasonal travel patterns |
Creates quarterly volatility |
| International licensing |
Can add revenue without equivalent U.S. sales costs |
The company’s revenue trajectory should be evaluated as a commercialization ramp, not as evidence of established mass-market demand. A small increase in prescriptions can produce a high percentage growth rate while leaving the company below operating break-even.
What are the principal financial risks?
The largest risk is operating leverage in reverse. ARAKODA requires commercial infrastructure, medical education, regulatory maintenance, distribution, and market access investment. If revenue growth slows, fixed costs can produce sustained losses.
Other financial risks include:
- Dependence on a single principal commercial product.
- Reliance on equity or debt financing.
- Exposure to government contract timing.
- Low bargaining power with distributors and wholesalers.
- Limited ability to offset price pressure with volume.
- Potential reimbursement resistance outside travel-clinic channels.
- Small commercial scale relative to larger antimalarial manufacturers.
The company’s financial performance is therefore more sensitive to execution than to broad malaria incidence. Most U.S. malaria-prophylaxis prescriptions are prevention prescriptions for travelers, not treatments for infected patients.
When does ARAKODA lose exclusivity?
ARAKODA’s FDA regulatory exclusivity and patent protection are separate issues. The FDA approved tafenoquine for malaria prophylaxis in 2018, while the active pharmaceutical ingredient had been known and previously developed for other malaria uses. That history weakens any assumption that the 2018 approval created broad new chemical entity protection.
FDA approval of ARAKODA did not create a standard five-year new chemical entity exclusivity period for the active ingredient. The product may receive orphan-drug exclusivity for the approved indication if the FDA orphan designation applies, but orphan exclusivity is indication-specific and does not prevent every competing tafenoquine product from entering unrelated indications.
The practical exclusivity analysis is:
| Protection category |
ARAKODA implication |
| New chemical entity exclusivity |
Generally not expected for an old active ingredient |
| Orphan-drug exclusivity |
Potentially relevant to the approved indication, subject to FDA designation and timing |
| Patent protection |
Depends on issued formulation, dosing, method, or manufacturing claims |
| Pediatric exclusivity |
No widely reported six-month extension should be assumed |
| Trade-secret protection |
May apply to manufacturing and commercial know-how but does not block an equivalent product |
| Trademark |
Protects the ARAKODA name, not tafenoquine itself |
Because patent expiration dates and claim scope depend on the relevant issued patents, Orange Book listings and current prosecution records must be reviewed on a live basis. A single patent expiration date should not be treated as the end of all ARAKODA protection.
What patents protect ARAKODA?
The core tafenoquine molecule is old relative to the ARAKODA approval date. Commercial protection therefore depends primarily on product-specific claims, including:
- Formulation claims.
- Tablet composition claims.
- Dosing regimens for prophylaxis.
- Patient-selection claims involving G6PD status.
- Methods for administering tafenoquine before and after travel.
- Manufacturing and salt-form claims.
- Combination or coadministration claims.
The strongest potential claims are those that require a generic sponsor to use the same approved dosing regimen or formulation. Broad method-of-use claims can create litigation leverage, but their practical value depends on whether a generic can design around the claims or market an alternative label.
Is ARAKODA listed in the Orange Book?
FDA Orange Book status is central to U.S. generic-entry risk. ARAKODA’s listing, if accompanied by patent information, can support a Paragraph IV certification and patent litigation under the Hatch-Waxman Act. The relevant questions are:
- Which patents are listed against NDA 210607?
- What are the patent expiration dates?
- Are the claims directed to the active ingredient, formulation, or method of use?
- Does each listed patent cover the proposed generic product?
- Is any patent delisted, expired, or vulnerable to an invalidity challenge?
The Orange Book does not automatically establish that a listed patent will survive litigation. It identifies the patents that the NDA holder has submitted for listing and that a generic applicant may need to address.
Which companies are challenging ARAKODA with Paragraph IV filings?
No major publicly reported Paragraph IV litigation against ARAKODA is broadly established in the public record available for this analysis. That does not eliminate generic risk. A generic applicant can file a certification that may not immediately produce high-visibility litigation, particularly if the sponsor has limited commercial exposure or if listed patents are few.
The most likely generic pathways are:
- An ANDA for tafenoquine tablets.
- A Paragraph III certification tied to patent expiry.
- A Paragraph IV certification challenging validity, enforceability, or infringement.
- A section viii statement carving out a protected method of use.
- A product with a label that avoids a particular patented prophylaxis regimen.
A section viii carve-out could be commercially important if the generic sponsor can sell tafenoquine for an unprotected use while avoiding the ARAKODA prophylaxis indication.
What generic launch scenarios exist for ARAKODA?
Scenario 1: No near-term ANDA challenge
ARAKODA retains brand pricing and prescriber differentiation. Revenue can grow through travel-clinic penetration and institutional sales, but the company remains exposed to low market volume.
Scenario 2: Paragraph IV challenge with litigation
The generic applicant may launch at risk or wait for litigation resolution. A settlement could establish a licensed or agreed entry date. The commercial impact would depend on the number of generic entrants and the scope of the settlement.
Scenario 3: Section viii label carve-out
A generic enters with a narrower label. This may reduce direct competition for the protected prophylaxis indication but still pressure pricing, distributor negotiations, and institutional procurement.
Scenario 4: Multiple generic entrants
Price erosion could be substantial because the underlying molecule is old and the market is price-sensitive. ARAKODA would need to defend share through adherence, service, supply reliability, and institutional contracts.
What patent litigation and settlement agreements affect ARAKODA?
No high-profile ARAKODA patent settlement or major publicly reported Hatch-Waxman judgment is identified in the available record. The absence of litigation is consistent with a small market where the expected value of litigation may be limited for both the sponsor and prospective generic companies.
A future settlement could include:
- A fixed generic launch date.
- Authorized-generic rights.
- Restrictions on the generic label.
- Supply or licensing terms.
- Allocation of litigation costs.
- No-challenge provisions, subject to antitrust limitations.
- Geographic restrictions outside the United States.
Any settlement should be assessed against the remaining patent term, likely generic launch economics, and the commercial value of the protected indication.
How strong is the ARAKODA patent estate?
ARAKODA’s patent estate appears strategically narrower than that of a recently launched novel chemical entity. The active ingredient is not new, and prophylaxis is an established antimalarial use. Protection is therefore more likely to depend on claim drafting around dosage, formulation, patient selection, and administration timing.
Patent-strength factors include:
| Factor |
Assessment |
| Active-ingredient exclusivity |
Weak relative to a new chemical entity |
| Formulation protection |
Potentially meaningful if technically specific and difficult to design around |
| Method-of-use protection |
Relevant if the approved regimen is covered and generic labeling cannot avoid it |
| Manufacturing protection |
Can raise technical barriers but may not prevent an equivalent finished product |
| Patent-term runway |
Must be determined patent by patent |
| Litigation leverage |
Limited by market size and potential design-around strategies |
| International coverage |
Likely uneven across jurisdictions |
The most durable barrier may be regulatory and commercial execution rather than molecule-level patent protection.
What FDA regulatory status does ARAKODA have?
ARAKODA is FDA-approved for malaria prophylaxis in adults. The label requires G6PD testing before use. The product is not a biologic and therefore does not face biosimilar competition. Any competing product would generally follow a small-molecule generic pathway rather than the FDA biosimilar pathway.
The FDA’s regulatory concerns center on hemolytic anemia, psychiatric effects, hypersensitivity, pregnancy and breastfeeding restrictions, and the need to avoid use in patients with deficient G6PD activity.[1]
Does ARAKODA face biosimilar risk?
No. ARAKODA is a small-molecule oral tablet, not a biologic. Its competitive risk is generic substitution, not biosimilar interchangeability.
The generic threat is still structurally important because tafenoquine tablets can potentially be developed through an ANDA if a sponsor can demonstrate pharmaceutical equivalence, bioequivalence, and compliance with applicable labeling and patent requirements.
What licensing and international expansion opportunities exist?
International licensing is a logical growth path because 60 Degrees can access markets without building a full commercial organization in every country. Potential partners include:
- Antimalarial distributors.
- Government procurement contractors.
- Military suppliers.
- Travel-health companies.
- Regional pharmaceutical manufacturers.
- Organizations serving malaria-endemic countries.
The economics depend on regulatory approval, local pricing, procurement requirements, supply commitments, and whether the partner receives exclusive territorial rights.
ARAKODA’s international opportunity is differentiated from its U.S. opportunity. In malaria-endemic countries, the product may have public-health value, but procurement prices can be low and tender competition can be severe. In travel markets, the product may support higher pricing but has lower volume.
What is the outlook for ARAKODA revenue?
The base case is continued revenue growth from a small base, accompanied by operating losses until sales scale materially. The strongest catalysts are:
- Expanded military or government procurement.
- Post-pandemic normalization of international travel.
- More travel-clinic adoption.
- Improved access to G6PD testing.
- International licensing.
- Additional tafenoquine indications or formulations.
- Evidence that weekly dosing improves adherence or patient satisfaction.
The principal downside catalysts are:
- Generic entry.
- Loss or reduction of government contracts.
- Weak travel demand.
- Pricing pressure from atovaquone/proguanil and doxycycline generics.
- Manufacturing or supply interruptions.
- Safety-related label changes.
- Financing dilution before profitability.
ARAKODA is best valued as a specialty commercial asset with binary execution risks, not as a conventional high-volume pharmaceutical franchise.
Key Takeaways
- ARAKODA is FDA-approved tafenoquine for adult malaria prophylaxis.
- 60 Degrees Pharmaceuticals is the principal U.S. commercial sponsor.
- Weekly dosing is the product’s main competitive advantage.
- G6PD testing is both a safety requirement and a market-access constraint.
- The active ingredient is old, so broad molecule-level exclusivity is limited.
- Generic risk depends on Orange Book listings, formulation claims, method-of-use claims, and ANDA timing.
- No major publicly reported Paragraph IV litigation or settlement is established in the available record.
- ARAKODA is exposed to generic competition, not biosimilar competition.
- Financial growth depends on scaling from a small base through travel medicine, government procurement, and international licensing.
- The company’s principal financial risk is continued operating loss and dependence on external capital before commercial scale is reached.
Frequently Asked Questions
Is ARAKODA the same drug as Krintafel?
No. Both contain tafenoquine, but ARAKODA is approved for malaria prophylaxis, while Krintafel is approved for preventing relapse of Plasmodium vivax malaria. Their labels, dosing, and regulatory exclusivity differ.
Can generic doxycycline replace ARAKODA?
Clinically, doxycycline is an alternative malaria-prophylaxis drug for appropriate patients. Commercially, generic doxycycline is a major price competitor because it is inexpensive and widely available.
Does ARAKODA require a prescription?
Yes. ARAKODA requires a prescription and quantitative G6PD testing before use.
What would most increase ARAKODA’s value?
A large government or military contract, successful international licensing, broader travel-clinic adoption, or an additional approved indication would have the greatest potential to increase commercial value.
Is ARAKODA likely to achieve blockbuster sales?
That outcome is unlikely under the current U.S. indication alone. The product addresses a limited prophylaxis market and competes with inexpensive generic drugs. Blockbuster economics would require substantial international expansion, institutional procurement, or new indications.
References
-
U.S. Food and Drug Administration. (2018). ARAKODA (tafenoquine succinate) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210607s000lbl.pdf
-
60 Degrees Pharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: ARAKODA application 210607. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman Letters and 30-month stays. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters-and-30-month-stays
